India Globalization Capital, Inc. (IGC) Announces Update On Phase 1 Clinical Trial on Alzheimer's Patients
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients
February 22, 2021 8:00 AM ESTPOTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (IGC or the Company) (NYSE American: IGC) is pleased to announce the progress of its tetrahydrocannabinol (THC)-based phase 1 clinical trial, which was approved to proceed by the U.S. Food and Drug Administration (FDA) on July 30, 2020, as previously disclosed.
On February 11, 2021, the Company completed administering the first of three levels of dosing of IGC-AD1, the Companys cannabinoid-based investigational new drug, on the first five of twelve patients suffering from Alzheimers disease. The Company continues to enroll the remaining patients.
Enrolling patients and... More